5-[4-(1-Methylindol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione | 172647-57-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-[4-(1-Methylindol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
• 英文别名: 5-[[4-[(1-methylindol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• CAS: 172647-57-3
• 化学式: C₂₀H₁₈N₂O₃S
• 分子量: 366.441
• InChiKey: HBNKWKOJRFCGGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  85.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-[4-(1-methylindol-2-ylmethoxy)benzyl]-3-triphenylmethylthiazolidine-2,4-dione 在 钯 作用下， 以 1,4-二氧六环 为溶剂， 以to give 1.49 g of the title compound, melting at 174.3-175.5° C.的产率得到5-[4-(1-Methylindol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
  参考文献：
  名称：

  Heterocyclic compounds having anti-diabetic activity and their use

  摘要：

  式（I）的化合物：##STR1## 其中：X代表未取代或取代的吲哚基，吲哚啉基，氮杂吲哚基，氮杂吲哚啉基，咪唑吡啶基或咪唑嘧啶基；Y代表氧或硫原子；Z代表2,4-二氧代噻唑烷-5-基甲基，2,4-二氧代噻唑烷-5-基甲基，2,4-二氧代噁唑烷-5-基甲基，3,5-二氧代噁唑烷-2-基甲基或N-羟基脲甲基基团；R代表氢原子，烷基，烷氧基，卤素原子，羟基，硝基，芳基烷基或未取代或取代的氨基基团；m为1至5的整数！具有降血糖和抗糖尿病活性。

  公开号：

  US05962470A1

文献信息

• Intermediate compounds in the preparation of heterocyclic compounds
  申请人：Sankyo Company, Limited

  公开号：US05739345A1

  公开（公告）日：1998-04-14

  Compounds of formula (I): ##STR1## \x9bwherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5! have hypoglycemic and anti-diabetic activities. Disclosed also are intermediate compounds for the preparation of compounds of formula I.

  式(I)的化合物：##STR1## 其中：X代表未取代或取代的吲哚基、吲哚啉基、氮杂吲哚基、氮杂吲哚啉基、咪唑吡啶基或咪唑嘧啶基；Y代表氧原子或硫原子；Z代表2,4-二氧代噻唑啉-5-亚甲基、2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噁唑啉-5-基甲基、3,5-二氧代氧杂噻唑啉-2-基甲基或N-羟基脲甲基；R代表氢原子、烷基、烷氧基、卤素原子、羟基、硝基、芳基烷基或未取代或取代的氨基；m为1至5的整数！具有降血糖和抗糖尿病活性。还公开了制备式(I)化合物的中间体化合物。
• Heterocyclic compound having anti-diabetic activity
  申请人：Sankyo Company, Limited

  公开号：US05977365A1

  公开（公告）日：1999-11-02

  Compounds of formula (I): ##STR1## [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrinidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxo-oxadiazolidin-2-ylmethyl or N-hydroxyureidom ethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an inzeger of from 1 to 5] have hypoglycemic and anti-diabetic activities.

  式(I)的化合物：##STR1## [其中：X代表未取代或取代的吲哚基、吲哚啉基、氮杂吲哚基、氮杂吲哚啉基、咪唑吡啶基或咪唑吡啶啉基；Y代表氧原子或硫原子；Z代表2,4-二氧代噻唑啉-5-亚甲基基、2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噁唑啉-5-基甲基、3,5-二氧代氧化噻唑啉-2-基甲基或N-羟基脲基乙基基团；R代表氢原子、烷基、烷氧基、卤原子、羟基、硝基、芳基烷基或未取代或取代的氨基基团；m为1至5的整数]具有降血糖和抗糖尿病活性。
• Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use
  申请人：Sankyo Company Limited

  公开号：EP1022274A1

  公开（公告）日：2000-07-26

  A compound of formula (XIV): wherein: each of Y and Y' independently represents an oxygen atom or a sulfur atom; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom. a hydroxy group, a nitro group, an aralkyl group, or a group of formula -NRaRb, wherein Ra and Rb are the same or different and each represents a hydrogen atom, an alkyl group, an aralkyl group, an aryl group, an aliphatic carboxylic acyl group, an aliphatic carboxylic acyl group which is substituted by an aryl group, or an aromatic carboxylic acyl group, m is an integer of from 1 to 5; Q represents a lower alkoxycarbonyl group, a formyl group, a protected formyl group or a carboxyl group; and salts thereof. The compound of formula (XIV) is of use as an intermediate in the synthesis of heterocyclic compounds having hypoglycemic and anti-diabetic activities.

  式(XIV)化合物： 其中 Y 和 Y'各自独立地代表氧原子或硫原子； R 代表氢原子、烷基、烷氧基、卤素原子、羟基、硝基、芳烷基或式 -NRaRb 的基团。 式-NRaRb、 其中 Ra 和 Rb 相同或不同，各自代表氢原子、烷基、芳烷基、芳基、脂肪族羧酰基、被芳基取代的脂肪族羧酰基或芳香族羧酰基、 m 是 1 至 5 的整数； Q 代表低级烷氧基羰基、甲酰基、受保护甲酰基或羧基；以及 其盐类。 式（XIV）化合物可用作合成具有降血糖和抗糖尿病活性的杂环化合物的中间体。
• Heterocyclic compounds having anti-diabetic activity, their preparation and their use
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0676398B1

  公开（公告）日：2001-10-24
• US5624935A
  申请人：——

  公开号：US5624935A

  公开（公告）日：1997-04-29